Oncomir miR-125b Suppresses p14ARF to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer
暂无分享,去创建一个
H. Kung | R. deVere White | Xubao Shi | Ai-Hong Ma | Xu-Bao Shi | Lingru Xue | Hsing-Jien Kung | Ralph W. deVere White | Sumaira Amir | L. Xue | A. Ma | S. Amir
[1] Goberdhan P Dimri,et al. Regulation of a Senescence Checkpoint Response by the E2F1 Transcription Factor and p14ARF Tumor Suppressor , 2000, Molecular and Cellular Biology.
[2] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[3] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[4] U. Kees,et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. , 2006, Cancer research.
[5] J L Cleveland,et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.
[6] Beiyan Zhou,et al. MicroRNA miR-125b causes leukemia , 2010, Proceedings of the National Academy of Sciences.
[7] G. Peters,et al. Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2 , 2002, Oncogene.
[8] B. Dörken,et al. p14ARF-induced Apoptosis in p53 Protein-deficient Cells Is Mediated by BH3-only Protein-independent Derepression of Bak Protein through Down-regulation of Mcl-1 and Bcl-xL Proteins , 2012, The Journal of Biological Chemistry.
[9] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[10] Charles J. Sherr,et al. The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.
[11] R. Murphy,et al. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. , 2006, Experimental and molecular pathology.
[12] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[13] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[14] D. Meek. Tumour suppression by p53: a role for the DNA damage response? , 2009, Nature Reviews Cancer.
[15] R. Plasterk,et al. The diverse functions of microRNAs in animal development and disease. , 2006, Developmental cell.
[16] C. Croce,et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[18] M. Umeda,et al. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. , 1989, Toxicology in vitro : an international journal published in association with BIBRA.
[19] Aamir Ahmad,et al. Recent updates on the role of microRNAs in prostate cancer , 2012, Journal of Hematology & Oncology.
[20] C. Croce,et al. MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.
[21] Q. Pan,et al. MicroRNA-143 as a tumor suppressor for bladder cancer. , 2009, The Journal of urology.
[22] C. Sherr,et al. Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.
[23] Jun Yu,et al. MicroRNA in colorectal cancer: from benchtop to bedside. , 2011, Carcinogenesis.
[24] G. Attard,et al. Prostate cancer in 2011: Redefining the therapeutic landscape for CRPC , 2012, Nature Reviews Urology.
[25] George A. Calin,et al. Expression of microRNAs and protein‐coding genes associated with perineural invasion in prostate cancer , 2008, The Prostate.
[26] Christopher P Evans,et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells , 2007, Proceedings of the National Academy of Sciences.
[27] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[28] S. Willis,et al. Life in the balance: how BH3-only proteins induce apoptosis. , 2005, Current opinion in cell biology.
[29] K. Ichimura,et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.
[30] C. Tepper,et al. miR‐125b promotes growth of prostate cancer xenograft tumor through targeting pro‐apoptotic genes , 2011, The Prostate.
[31] A. Deitch,et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors , 1998, Cancer.
[32] J. Moul,et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. , 1995, The Journal of urology.
[33] H. Van Poppel,et al. Emerging novel therapies for advanced prostate cancer , 2012, Therapeutic advances in urology.
[34] W. W. Nichols,et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.
[35] E. Gelmann,et al. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. , 1997, Journal of the National Cancer Institute.
[36] N. Dawson,et al. Emerging therapies in castrate-resistant prostate cancer , 2009, Current opinion in oncology.
[37] Mitsutoshi Nakamura,et al. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. , 2002, The American journal of pathology.
[38] R. deVere White,et al. p53 in prostate cancer: frequent expressed transition mutations. , 1994, Journal of the National Cancer Institute.
[39] C. Croce,et al. MicroRNAs in Cancer. , 2009, Annual review of medicine.
[40] C. Tepper,et al. microRNAs and prostate cancer , 2008, Journal of cellular and molecular medicine.
[41] S. Goff,et al. Inhibition of v-Abl transformation by p53 and p19ARF , 1999, Oncogene.